Abnormal Ca2+ homeostasis is characteristic of MD, and some Ca2+ regulators (Orai, TRPC3, and NFAT) can be considered as therapeutic targets for MDs. The gene discussed is TRPC3; the disease is myelodysplastic syndrome.